Clinical Trial Update: A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia [Phase 2]

View source ↗

Summary

Pfizer conducted a Phase 2 dose-ranging multicenter trial of PD 0200390 in adults with primary insomnia, and the study status is shown as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• PD 0200390

Snippet

Sponsor: Pfizer | Conditions: Primary Insomnia | Phase 2 | Status: COMPLETED